Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
29
AGN.CX Quote, Financials, Valuation and Earnings
Last price:
$0.08
Seasonality move
:
31.42%
Day range:
$0.08 - $0.08
52-week range:
$0.06 - $0.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.57x
Volume:
27.8K
Avg. volume:
13.8K
1-year change:
6.67%
Market cap:
$2.7M
Revenue:
--
EPS (TTM):
-$0.06
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AGN.CX
Algernon Health, Inc.
|
-- | -- | -- | -- | -- |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AGN.CX
Algernon Health, Inc.
|
$0.08 | -- | $2.7M | -- | $0.00 | 0% | -- |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
$0.04 | -- | $6.8M | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0250 | -- | $256.9K | 0.65x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AGN.CX
Algernon Health, Inc.
|
-- | 0.270 | -- | 0.03x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
40.99% | -3.518 | 19.05% | 2.85x |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AGN.CX
Algernon Health, Inc.
|
-$8.7K | -$583.2K | -96.85% | -96.85% | -- | -$174.5K |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -$1.1M | -1117.27% | -- | -- | -$408.2K |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
Algernon Health, Inc. vs. Competitors
-
Which has Higher Returns AGN.CX or COOL.CX?
Core One Labs, Inc. has a net margin of -- compared to Algernon Health, Inc.'s net margin of --. Algernon Health, Inc.'s return on equity of -96.85% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGN.CXAlgernon Health, Inc.-- -$0.02 $1.7M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About AGN.CX or COOL.CX?
Algernon Health, Inc. has a consensus price target of --, signalling upside risk potential of 3103.13%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Algernon Health, Inc. has higher upside potential than Core One Labs, Inc., analysts believe Algernon Health, Inc. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AGN.CXAlgernon Health, Inc.0 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is AGN.CX or COOL.CX More Risky?
Algernon Health, Inc. has a beta of 1.326, which suggesting that the stock is 32.63% more volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock AGN.CX or COOL.CX?
Algernon Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Algernon Health, Inc. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGN.CX or COOL.CX?
Algernon Health, Inc. quarterly revenues are --, which are larger than Core One Labs, Inc. quarterly revenues of --. Algernon Health, Inc.'s net income of -$583.2K is higher than Core One Labs, Inc.'s net income of --. Notably, Algernon Health, Inc.'s price-to-earnings ratio is -- while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Algernon Health, Inc. is -- versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGN.CXAlgernon Health, Inc.-- -- -- -$583.2K COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns AGN.CX or CURE.X.CX?
Biocure Technology has a net margin of -- compared to Algernon Health, Inc.'s net margin of --. Algernon Health, Inc.'s return on equity of -96.85% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGN.CXAlgernon Health, Inc.-- -$0.02 $1.7M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About AGN.CX or CURE.X.CX?
Algernon Health, Inc. has a consensus price target of --, signalling upside risk potential of 3103.13%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Algernon Health, Inc. has higher upside potential than Biocure Technology, analysts believe Algernon Health, Inc. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings AGN.CXAlgernon Health, Inc.0 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is AGN.CX or CURE.X.CX More Risky?
Algernon Health, Inc. has a beta of 1.326, which suggesting that the stock is 32.63% more volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AGN.CX or CURE.X.CX?
Algernon Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Algernon Health, Inc. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGN.CX or CURE.X.CX?
Algernon Health, Inc. quarterly revenues are --, which are larger than Biocure Technology quarterly revenues of --. Algernon Health, Inc.'s net income of -$583.2K is higher than Biocure Technology's net income of --. Notably, Algernon Health, Inc.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Algernon Health, Inc. is -- versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGN.CXAlgernon Health, Inc.-- -- -- -$583.2K CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns AGN.CX or HEAL.CX?
has a net margin of -- compared to Algernon Health, Inc.'s net margin of --. Algernon Health, Inc.'s return on equity of -96.85% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGN.CXAlgernon Health, Inc.-- -$0.02 $1.7M HEAL.CX-- -- -- -
What do Analysts Say About AGN.CX or HEAL.CX?
Algernon Health, Inc. has a consensus price target of --, signalling upside risk potential of 3103.13%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Algernon Health, Inc. has higher upside potential than , analysts believe Algernon Health, Inc. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings AGN.CXAlgernon Health, Inc.0 0 0 HEAL.CX0 0 0 -
Is AGN.CX or HEAL.CX More Risky?
Algernon Health, Inc. has a beta of 1.326, which suggesting that the stock is 32.63% more volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AGN.CX or HEAL.CX?
Algernon Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Algernon Health, Inc. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGN.CX or HEAL.CX?
Algernon Health, Inc. quarterly revenues are --, which are larger than quarterly revenues of --. Algernon Health, Inc.'s net income of -$583.2K is higher than 's net income of --. Notably, Algernon Health, Inc.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Algernon Health, Inc. is -- versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGN.CXAlgernon Health, Inc.-- -- -- -$583.2K HEAL.CX-- -- -- --
-
Which has Higher Returns AGN.CX or LOBE.CX?
Lobe Sciences Ltd. has a net margin of -- compared to Algernon Health, Inc.'s net margin of --. Algernon Health, Inc.'s return on equity of -96.85% beat Lobe Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGN.CXAlgernon Health, Inc.-- -$0.02 $1.7M LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M -
What do Analysts Say About AGN.CX or LOBE.CX?
Algernon Health, Inc. has a consensus price target of --, signalling upside risk potential of 3103.13%. On the other hand Lobe Sciences Ltd. has an analysts' consensus of -- which suggests that it could grow by 20317.62%. Given that Lobe Sciences Ltd. has higher upside potential than Algernon Health, Inc., analysts believe Lobe Sciences Ltd. is more attractive than Algernon Health, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AGN.CXAlgernon Health, Inc.0 0 0 LOBE.CXLobe Sciences Ltd.0 0 0 -
Is AGN.CX or LOBE.CX More Risky?
Algernon Health, Inc. has a beta of 1.326, which suggesting that the stock is 32.63% more volatile than S&P 500. In comparison Lobe Sciences Ltd. has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.507%.
-
Which is a Better Dividend Stock AGN.CX or LOBE.CX?
Algernon Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lobe Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Algernon Health, Inc. pays -- of its earnings as a dividend. Lobe Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGN.CX or LOBE.CX?
Algernon Health, Inc. quarterly revenues are --, which are smaller than Lobe Sciences Ltd. quarterly revenues of --. Algernon Health, Inc.'s net income of -$583.2K is higher than Lobe Sciences Ltd.'s net income of -$1.1M. Notably, Algernon Health, Inc.'s price-to-earnings ratio is -- while Lobe Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Algernon Health, Inc. is -- versus -- for Lobe Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGN.CXAlgernon Health, Inc.-- -- -- -$583.2K LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M
-
Which has Higher Returns AGN.CX or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -- compared to Algernon Health, Inc.'s net margin of --. Algernon Health, Inc.'s return on equity of -96.85% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGN.CXAlgernon Health, Inc.-- -$0.02 $1.7M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About AGN.CX or NSHS.CX?
Algernon Health, Inc. has a consensus price target of --, signalling upside risk potential of 3103.13%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Algernon Health, Inc. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Algernon Health, Inc. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AGN.CXAlgernon Health, Inc.0 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is AGN.CX or NSHS.CX More Risky?
Algernon Health, Inc. has a beta of 1.326, which suggesting that the stock is 32.63% more volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock AGN.CX or NSHS.CX?
Algernon Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Algernon Health, Inc. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGN.CX or NSHS.CX?
Algernon Health, Inc. quarterly revenues are --, which are smaller than NanoSphere Health Sciences, Inc. quarterly revenues of --. Algernon Health, Inc.'s net income of -$583.2K is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Algernon Health, Inc.'s price-to-earnings ratio is -- while NanoSphere Health Sciences, Inc.'s PE ratio is 0.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Algernon Health, Inc. is -- versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGN.CXAlgernon Health, Inc.-- -- -- -$583.2K NSHS.CXNanoSphere Health Sciences, Inc.-- 0.65x -- -$13.1K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 21.85% over the past day.
Sell
33
ZBIO alert for Dec 16
Zenas BioPharma, Inc. [ZBIO] is down 19.73% over the past day.
Sell
38
HUT alert for Dec 16
Hut 8 Corp. [HUT] is down 14.21% over the past day.
